Tonix Pharmaceuticals stock halted ahead of FDA approval news
On Tuesday, Truist Securities reaffirmed its Buy rating on Palomar Holdings (NASDAQ:PLMR) with a consistent price target of $178.00. The stock, currently trading at $156.75 and near its 52-week high, has delivered an impressive 87% return over the past year. Truist analysts highlighted Palomar’s first-quarter performance, which surpassed expectations with an adjusted earnings per share (EPS) of $1.87. This figure notably exceeded both Truist’s own forecast of $1.71 and the consensus estimate of $1.59. The outperformance was partly attributed to a reserve gain that contributed $0.12 to the bottom line.
Palomar’s total operating revenue for the quarter was reported at $177.0 million, marginally surpassing Truist’s projection of $175.4 million and significantly outpacing the consensus of $164.2 million. According to InvestingPro data, the company maintains a "GREAT" overall financial health score of 3.55/5, with revenue growing at 47% over the last twelve months. The company’s net earned premiums showed a robust year-over-over increase of 52%, reaching $164.1 million and topping Truist’s estimate of $162.8 million.
The company’s net investment income for the quarter also slightly exceeded expectations, coming in at $12.1 million, just a notch above the $12.0 million forecasted by Truist. Additionally, Palomar’s effective tax rate for the quarter was lower than anticipated, at 20.1% compared to the estimated 22.0%. InvestingPro analysis reveals 14 additional key insights about Palomar’s performance and valuation, available to subscribers.
Closing out the financial highlights, Palomar Holdings reported an annualized adjusted return on equity (ROE) of 27.0% for the period, underscoring the company’s profitability and financial performance during the first quarter. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading near its fair value, with a market capitalization of $4.2 billion and a P/E ratio of 34x.
In other recent news, Palomar Holdings reported first-quarter earnings that exceeded expectations, with an Operating Earnings Per Share (EPS) of $1.87, surpassing both JMP Securities’ estimate of $1.49 and the consensus of $1.59. This strong performance was driven by a favorable consolidated loss ratio and a 20% increase in top-line growth. Evercore ISI responded by raising Palomar’s stock price target to $163, citing the company’s solid growth in earthquake coverage and robust expansion in Inland Marine & Other Property lines. Truist Securities also increased its price target to $178, highlighting a 33% growth in E&S premium and potential benefits from lower reinsurance costs.
Conversely, Keefe, Bruyette & Woods reduced their price target to $145, maintaining an Outperform rating and emphasizing Palomar’s strategic moves like new product launches and recruitment of underwriters. JPMorgan upgraded Palomar’s stock rating from Neutral to Overweight and raised the price target to $150, expressing confidence in the company’s growth potential despite a challenging macroeconomic environment. These developments reflect a mixed but generally positive outlook from analysts, who recognize Palomar’s strategic initiatives and strong financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.